SCHEDULE: Dellora Investments Discloses Stake in Tenax Therapeutics

Dellora Investments Master Fund LP, Dellora Investments LP, and Kevin Pyun have collectively reported beneficial ownership of 2.3% of Tenax Therapeutics' common stock as of March 31, 2026.

Summary

• Dellora Investments Master Fund LP, Dellora Investments LP, and Kevin Pyun have filed a Schedule 13G, indicating their beneficial ownership of Tenax Therapeutics, Inc. common stock.
• As of March 31, 2026, Dellora Investments Master Fund LP beneficially owns 345,257 shares, representing 2.0% of the class.
• Dellora Investments LP and Kevin Pyun each beneficially own 394,665 shares, representing 2.3% of the class.
• The ownership percentage is based on 17,197,613 shares of common stock outstanding as of March 6, 2026, as reported by Tenax Therapeutics in its Form 10-K filed on March 10, 2026.
• Dellora Investments LP is registered as an investment adviser and serves as the investment adviser to private funds, including Dellora Investments Master Fund LP.
• Kevin Pyun, as Principal of Dellora Investments LP, has investment and voting discretion over the shares held by the funds.
• Dellora Investments LP and Kevin Pyun expressly disclaim beneficial ownership over any of the securities reported, and this filing does not constitute an admission of beneficial ownership.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It provides factual information about ownership stakes without indicating positive or negative performance or strategic shifts for Tenax Therapeutics.

Positives

• Significant reporting entities (Dellora Investments Master Fund LP, Dellora Investments LP, Kevin Pyun) have disclosed their holdings, providing transparency to the market.
• The reporting entities collectively hold a notable stake, indicating confidence or strategic interest in Tenax Therapeutics.

Negatives

• Dellora Investments LP and Kevin Pyun expressly disclaim beneficial ownership, which could introduce ambiguity regarding ultimate control or intent.
• The filing does not provide specific reasons for the investment or any strategic plans involving Tenax Therapeutics.

Risks

• The disclaimer of beneficial ownership by Dellora Investments LP and Kevin Pyun could be interpreted as a lack of commitment or a strategy to avoid certain regulatory implications.
• The filing does not detail any specific risks associated with the investment or the company itself, as this is a Schedule 13G filing focused on ownership.

Future Outlook

This filing is a Schedule 13G, which reports passive ownership stakes and does not contain forward-looking statements or guidance from the company itself. The future outlook for Tenax Therapeutics would be found in other SEC filings by the company.

Management Comments

• Dellora Investments LP and Mr. Pyun expressly disclaim beneficial ownership over any of the securities reported in this statement, and the filing of this statement shall not be construed as an admission that Dellora Investments LP or Mr. Pyun are the beneficial owner of any of the securities reported herein.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. This filing indicates that Dellora Investments is a notable holder in the biotechnology or pharmaceutical sector, where Tenax Therapeutics operates, and suggests a passive investment approach rather than an attempt to control the company.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant ownership stakes, potentially influencing market perception.
• Management of Tenax Therapeutics: Awareness of substantial passive investors, which may be relevant for future strategic decisions or capital raises.

Next Steps

• Monitor future filings by Dellora Investments and Tenax Therapeutics for any changes in ownership or strategic developments.
• Observe Tenax Therapeutics' performance and disclosures for insights into the company's operational and financial health.

Key Dates

Keywords

Schedule 13G, Tenax Therapeutics, Dellora Investments, Beneficial Ownership, Common Stock, Investment Adviser, SEC Filing, Ownership Disclosure